Sacituzumab tirumotecan–pembrolizumab has efficacy in PD-L1-negative NSCLC
來源 Nature 生命科学16 小時前
Summary
This item is a 英文-language original; headline and summary shown as published.
本站僅提供標題與摘要索引，完整內容與版權均歸原發布方所有，請點擊原文連結閱讀。
前往原文- 所屬頻道
- 科學
- 所屬地區
- 全球視角
- Language
- English
- Item ID
- science-f8f5fd76
Comments 0 comments
No comments yet. Be the first.